SG10201500027TA - Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor - Google Patents

Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor

Info

Publication number: SG10201500027TA
Authority: SG; Singapore
Prior art keywords: phenyl; decan; diaza; spiro; trifluoromethyl
Prior art date: 2006-04-05

Application number

SG10201500027TA

Inventor

Mengwei Hu

Sunil Paliwal

Neng-Yang Shih

Frank Guenter

Ingrid Mergelsberg

Original Assignee

Opko Health Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-05

Filing date

2007-04-04

Publication date

2015-02-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38542035&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201500027T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-04-04 Application filed by Opko Health Inc filed Critical Opko Health Inc

2015-02-27 Publication of SG10201500027TA publication Critical patent/SG10201500027TA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG10201500027TA 2006-04-05 2007-04-04 Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor SG10201500027TA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US78928006P	2006-04-05	2006-04-05

Publications (1)

Publication Number	Publication Date
SG10201500027TA true SG10201500027TA (en)	2015-02-27

Family

ID=38542035

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201500027TA SG10201500027TA (en)	2006-04-05	2007-04-04	Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
SG201102463-5A SG170838A1 (en)	2006-04-05	2007-04-04	Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}- methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG201102463-5A SG170838A1 (en)	2006-04-05	2007-04-04	Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}- methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor

Country Status (16)

Country	Link
US (5)	US8178550B2 (en)
EP (4)	EP2004646B1 (en)
JP (3)	JP5352446B2 (en)
CN (2)	CN102276606B (en)
AR (1)	AR060353A1 (en)
CA (1)	CA2648604C (en)
ES (1)	ES2584838T3 (en)
HU (2)	HUE028908T2 (en)
LT (1)	LTPA2017031I1 (en)
MX (1)	MX2008012935A (en)
PE (3)	PE20120545A1 (en)
PL (1)	PL2004646T3 (en)
PT (1)	PT2004646T (en)
SG (2)	SG10201500027TA (en)
TW (1)	TWI363058B (en)
WO (1)	WO2007117486A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20030762A1 (en)	2001-12-18	2003-09-05	Schering Corp	HETEROCYCLIC COMPOUNDS AS NK1 ANTAGONISTS
CN103751186B (en)	2006-04-05	2016-08-24	欧科生医股份有限公司	The salt of pharmaceutical preparation: 8-[{ 1-(3,5-double-(trifluoromethyl) phenyl)-ethyoxyl }-methyl]-8-phenyl-1,7-diaza-spiro [4.5] decyl-2-ketone and the method treated with it
EP2004646B1 (en)	2006-04-05	2016-06-08	OPKO Health, Inc.	Hydrochloride salt of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
PE20081891A1 (en) *	2007-03-22	2008-12-27	Opko Health Inc	TABLET FORMULATIONS CONTAINING SALTS OF 8 - [{1- (3,5-BIS- (TRIFLUOROMETIL) PHENYL) -ETOXY} -METIL] -8-PHENYL-1,7-DIAZA-SPIRO [4.5] DECAN-2- ONA AND TABLETS MADE FROM THESE
AR066191A1 (en) *	2007-03-22	2009-08-05	Schering Corp	PROCESS AND INTERMEDIARIES FOR THE SYNTHESIS OF COMPOUNDS 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) PHENYL) - ETOXI) - METAL] - 8 PHENYL - 1,7- DIAZA - ESPIRO (4, 5) DECAN - 2 ONA
KR101719004B1 (en)	2008-09-05	2017-03-22	옵코 헬스, 인크.	8-1-35-----8--17--4.5-2- Process and intermediates for the synthesis of 8-1-35-bis-trifluoromethylphenyl-ethoxy-methyl-8-phenyl-17-diaza-spiro4.5decan-2-one compounds
EP3143996A1 (en) *	2009-08-14	2017-03-22	OPKO Health, Inc.	Intravenous formulations of neurokinin 1-antagonists
CN105017251B (en) *	2015-06-30	2018-06-29	齐鲁制药有限公司	A kind of Preparation Method And Their Intermediate of nk 1 receptor antagonist
FR3047665B1 (en)	2016-02-17	2020-12-11	Pf Medicament	CELASTROL AND ITS DERIVATIVES IN THE TREATMENT OF PRE-CANCEROUS SKIN TUMORS AND PATHOLOGIES
CN106866669A (en) *	2017-04-19	2017-06-20	成都百特万合医药科技有限公司	A kind of method for synthesizing the smooth intermediate of roller pyrrole
EP4003512A1 (en) *	2019-07-25	2022-06-01	Intervet International B.V.	Crystalline form of telmapitant or (5r,8s)-8-[[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione
BR112022018876A2 (en)	2020-04-03	2022-11-22	Nerre Therapeutics Ltd	NK-1 RECEPTOR ANTAGONIST TO TREAT A DISEASE SELECTED FROM SEPSIS, septic shock, acute respiratory distress syndrome (ARDS) or MULTIPLE ORGAN DYSFUNCTION SYNDROME
WO2021245512A1 (en)	2020-06-02	2021-12-09	Nerre Therapeutics Limited	Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE188472T1 (en)	1992-10-28	2000-01-15	Merck Sharp & Dohme	4-ARYLMETHYLOXYMETHYL PIPERIDINE AS TACHYKININ ANTAGONISTS
JPH08504435A (en)	1992-12-14	1996-05-14	メルクシヤープエンドドームリミテツド	4-Aminomethyl / thiomethyl / sulfonylmethyl-4-phenylpiperidine as tachykinin receptor antagonists
AU685212B2 (en)	1994-01-13	1998-01-15	Merck Sharp & Dohme Limited	Gem-disubstituted azacyclic tachykinin antagonists
EP0858341B1 (en)	1995-08-28	2001-10-24	Schering Corporation	Combination therapy for advanced cancer comprising temozolomide and cisplatin
US5939098A (en)	1996-09-19	1999-08-17	Schering Corporation	Cancer treatment with temozolomide
WO1999001444A1 (en)	1997-07-02	1999-01-14	Merck & Co., Inc.	Polymorphic form of the tachykinin receptor antagonist 2-(r)-(1-(r) -(3,5-bis(trifluoromethyl) phenyl)ethoxy)-3-(s)-(4-fluoro) phenyl-4-(3-5 (-oxo-1h,4h-1,2,4,-triazolo) methylmorpholine
WO2002064557A2 (en) *	2001-02-12	2002-08-22	Teva Pharmaceutical Industries Ltd.	New crystal forms of oxcarbazepine and processes for their preparation
PE20030762A1 (en)	2001-12-18	2003-09-05	Schering Corp	HETEROCYCLIC COMPOUNDS AS NK1 ANTAGONISTS
US7534913B2 (en) *	2002-07-18	2009-05-19	Teva Pharmaceutica Industries Ltd.	Crystalline form of nateglinide
EP1575962A1 (en) *	2002-12-24	2005-09-21	Teva Pharmaceutical Industries Limited	Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
GB0321256D0 (en) *	2003-09-11	2003-10-08	Generics Uk Ltd	Novel crystalline compounds
CA2550432A1 (en) *	2003-12-22	2005-07-14	Schering Corporation	Pharmaceutical compositions
TWI303246B (en)	2004-04-07	2008-11-21	Schering Corp	Fused ring nk1 antagonists
MY142804A (en) *	2004-07-01	2011-01-14	Opko Health Inc	Nk1 antagonists
CA2585446A1 (en)	2004-11-09	2006-05-18	Schering Corporation	Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level
CN103751186B (en)	2006-04-05	2016-08-24	欧科生医股份有限公司	The salt of pharmaceutical preparation: 8-[{ 1-(3,5-double-(trifluoromethyl) phenyl)-ethyoxyl }-methyl]-8-phenyl-1,7-diaza-spiro [4.5] decyl-2-ketone and the method treated with it
CL2007000947A1 (en)	2006-04-05	2008-01-25	Schering Corp	Crystalline forms of the salts of esylate, oxalate, mesylate and maleate of 8 - [[1- (3,5-bis- (trifluoromethyl) phenyl) -ethoxy] -methyl] -8-phenyl-1,7-diaza-spiro [4.5] decan-2-one; pharmaceutical composition; and use in the preparation of a medicament for the treatment and / or prevention of emesis and / or nausea.
EP2004646B1 (en)	2006-04-05	2016-06-08	OPKO Health, Inc.	Hydrochloride salt of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
BRPI0716026A2 (en) *	2006-08-07	2013-08-06	Stiefel Laboratories	crystalline antifungal compounds
AR066191A1 (en)	2007-03-22	2009-08-05	Schering Corp	PROCESS AND INTERMEDIARIES FOR THE SYNTHESIS OF COMPOUNDS 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) PHENYL) - ETOXI) - METAL] - 8 PHENYL - 1,7- DIAZA - ESPIRO (4, 5) DECAN - 2 ONA
PE20081891A1 (en)	2007-03-22	2008-12-27	Opko Health Inc	TABLET FORMULATIONS CONTAINING SALTS OF 8 - [{1- (3,5-BIS- (TRIFLUOROMETIL) PHENYL) -ETOXY} -METIL] -8-PHENYL-1,7-DIAZA-SPIRO [4.5] DECAN-2- ONA AND TABLETS MADE FROM THESE
KR101719004B1 (en)	2008-09-05	2017-03-22	옵코 헬스, 인크.	8-1-35-----8--17--4.5-2- Process and intermediates for the synthesis of 8-1-35-bis-trifluoromethylphenyl-ethoxy-methyl-8-phenyl-17-diaza-spiro4.5decan-2-one compounds
EP3143996A1 (en)	2009-08-14	2017-03-22	OPKO Health, Inc.	Intravenous formulations of neurokinin 1-antagonists

2007
- 2007-04-04 EP EP07774640.2A patent/EP2004646B1/en not_active Revoked
- 2007-04-04 PE PE2011001795A patent/PE20120545A1/en active IP Right Grant
- 2007-04-04 PE PE2007000413A patent/PE20071220A1/en active IP Right Grant
- 2007-04-04 PL PL07774640.2T patent/PL2004646T3/en unknown
- 2007-04-04 HU HUE07774640A patent/HUE028908T2/en unknown
- 2007-04-04 MX MX2008012935A patent/MX2008012935A/en active IP Right Grant
- 2007-04-04 EP EP13179415.8A patent/EP2662374A1/en not_active Withdrawn
- 2007-04-04 SG SG10201500027TA patent/SG10201500027TA/en unknown
- 2007-04-04 JP JP2009504269A patent/JP5352446B2/en not_active Expired - Fee Related
- 2007-04-04 ES ES07774640.2T patent/ES2584838T3/en active Active
- 2007-04-04 US US11/732,548 patent/US8178550B2/en active Active
- 2007-04-04 WO PCT/US2007/008344 patent/WO2007117486A2/en active Application Filing
- 2007-04-04 PT PT77746402T patent/PT2004646T/en unknown
- 2007-04-04 AR ARP070101438A patent/AR060353A1/en not_active Application Discontinuation
- 2007-04-04 SG SG201102463-5A patent/SG170838A1/en unknown
- 2007-04-04 CA CA2648604A patent/CA2648604C/en active Active
- 2007-04-04 EP EP13179376.2A patent/EP2662373A1/en not_active Withdrawn
- 2007-04-04 CN CN2011101619320A patent/CN102276606B/en not_active Expired - Fee Related
- 2007-04-04 TW TW096112166A patent/TWI363058B/en not_active IP Right Cessation
- 2007-04-04 EP EP13179424.0A patent/EP2676957A1/en not_active Withdrawn
- 2007-04-04 PE PE2014000758A patent/PE20142329A1/en not_active Application Discontinuation
- 2007-04-04 CN CN200780015817.4A patent/CN101437821B/en not_active Expired - Fee Related
2009
- 2009-11-06 US US12/614,108 patent/US8470842B2/en active Active
2012
- 2012-11-19 JP JP2012253653A patent/JP5856944B2/en not_active Expired - Fee Related
2013
- 2013-06-21 US US13/923,859 patent/US20130281477A1/en not_active Abandoned
2014
- 2014-09-25 JP JP2014194788A patent/JP6122411B2/en active Active
2015
- 2015-04-10 US US14/683,871 patent/US10196394B2/en active Active
2017
- 2017-10-16 HU HUS1700037C patent/HUS1700037I1/en unknown
- 2017-10-16 LT LTPA2017031C patent/LTPA2017031I1/en unknown
2019
- 2019-01-09 US US16/243,404 patent/US20190375751A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20070244142A1 (en)	2007-10-18
TWI363058B (en)	2012-05-01
JP6122411B2 (en)	2017-04-26
US8178550B2 (en)	2012-05-15
HUS1700037I1 (en)	2017-11-28
JP2013032404A (en)	2013-02-14
US10196394B2 (en)	2019-02-05
US20150210693A1 (en)	2015-07-30
WO2007117486A2 (en)	2007-10-18
CN102276606A (en)	2011-12-14
CA2648604A1 (en)	2007-10-18
PE20071220A1 (en)	2007-12-14
PE20120545A1 (en)	2012-05-21
EP2004646B1 (en)	2016-06-08
JP2014240437A (en)	2014-12-25
ES2584838T3 (en)	2016-09-29
JP2009532472A (en)	2009-09-10
EP2662374A1 (en)	2013-11-13
EP2662373A1 (en)	2013-11-13
AR060353A1 (en)	2008-06-11
PL2004646T3 (en)	2016-12-30
HUE028908T2 (en)	2017-01-30
WO2007117486A3 (en)	2008-02-14
US20100048601A1 (en)	2010-02-25
LTPA2017031I1 (en)	2017-11-10
SG170838A1 (en)	2011-05-30
CN102276606B (en)	2013-06-12
US20190375751A1 (en)	2019-12-12
PE20142329A1 (en)	2015-01-30
JP5352446B2 (en)	2013-11-27
EP2676957A1 (en)	2013-12-25
TW200815439A (en)	2008-04-01
PT2004646T (en)	2016-07-14
JP5856944B2 (en)	2016-02-10
EP2004646A2 (en)	2008-12-24
CN101437821B (en)	2014-06-04
MX2008012935A (en)	2008-10-15
CA2648604C (en)	2016-05-24
US20130281477A1 (en)	2013-10-24
US8470842B2 (en)	2013-06-25
CN101437821A (en)	2009-05-20

Publication	Publication Date	Title
HUS1700037I1 (en)	2017-11-28	Hydrochloride salt of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
TWI350185B (en)	2011-10-11	Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4,5]decan-2-one salts and tablets made therefrom
SG10201500028RA (en)	2015-02-27	Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
HRP20130536T1 (en)	2013-07-31	Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
AP2010005453A0 (en)	2010-12-31	Triazine compounds as P13 kinase and MTOR inhibitors.
EP2120959A4 (en)	2010-05-26	Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
EP1983831A4 (en)	2010-11-24	Phenyl and pyridyl compounds for inflammation and immune-related uses
EP1843805A4 (en)	2015-05-06	Antimicrobial needle coating for extended infusion
GB0403635D0 (en)	2004-03-24	Pyridinocarboxamides with improved activity as kinase inhibitors
SI2097381T1 (en)	2013-11-29	4-S4-(sS4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)CCARBAMOYLcAMINO)-3-FLUOROPHENOXYC-N-METHYLPYRIDINE-2-CARBOXAMIDE MONOHYDRATE
EP1988551A4 (en)	2012-04-25	Core catcher and its manufacturing method, and reactor container and its modifying method
EP2048204A4 (en)	2010-09-15	Yellow ink composition, ink set, ink cartridge, inkjet recording method and recorded matter
IL194770A0 (en)	2009-08-03	6-(4-cyclopropylpiperazin-1-yl)-2'-methyl-[3,4']-bipyridine and its use as a medicament
HK1158623A1 (en)	2012-07-20	Intermediates for the synthesis of 8-[1-(3,5-bis-(trifluoromethyl)phenyl)- ethoxy-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds 8-[1-(35--())--]-8--17-- [45]-2-
ZA200901548B (en)	2010-02-24	Methods for administering long-lasting hypoglycemic agents
HK1110092A1 (en)	2008-07-04	A binder composition,a construction composition comprising said binder composition,as well as a method for preparing the construction composition and use thereof
PL393312A1 (en)	2011-04-26	Filter cartridge and method for manufacturing and using the filter cartridge
ZA200606606B (en)	2008-02-27	Substituted Azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
IL206492A (en)	2015-04-30	Spirocyclic heterocycles and such compounds for use as a medicaments, optionally with another active substance
IL212179A0 (en)	2011-06-30	Nitrogenous heterocyclic compounds, preparation thereof, and use thereof as antibacterial agents
GB0819432D0 (en)	2008-12-03	Compound, composition and use
WO2007114922A3 (en)	2008-01-17	Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
GB0609309D0 (en)	2006-06-21	Compound, Ink, Process And Use
PL2350108T3 (en)	2015-08-31	C-glycoside compounds, and method for preparing c-glycoside compounds
ZA200708153B (en)	2008-10-29	Phosphate salts of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxycyclohexane